Target trial emulation of early docetaxel and enzalutamide for metastatic hormone‐sensitive prostate cancer
Early docetaxel did not appear to improve survival when added to enzalutamide, regardless of disease volume, whereas it did appear to improve survival when enzalutamide was not used, particularly in high-volume disease. While residual confounding could not be excluded, these findings do not support the routine addition of early docetaxel to enzalutamide in mHSPC.
Authors
- Christopher J. Sweeney (ORCID: https://orcid.org/0000-0002-0398-6018)
- Ian C. Marschner (ORCID: https://orcid.org/0000-0002-6225-1572)
- Yu Yang Soon (ORCID: https://orcid.org/0000-0002-1995-2170)
- I. Manjula Schou
- Martin R. Stockler (ORCID: https://orcid.org/0000-0003-3793-8724)
- Ian D. Davis (ORCID: https://orcid.org/0000-0002-9066-8244)
- Andrew Martin
Institutions
- The University of Sydney (AU)
- The University of Queensland (AU)
- National University of Singapore (SG)
- Concord Repatriation General Hospital (AU)
- Chris O’Brien Lifehouse (AU)
- Eastern Health (AU)
- National University Cancer Institute, Singapore (SG)
- Centre for Cancer Biology (AU)
- Australian and New Zealand Urogenital and Prostate Cancer Trials Group (AU)
- National Health and Medical Research Council (AU)
- Monash University (AU)
- The University of Adelaide (AU)
Publication Details
- Journal
- British Journal of Urology
- Published
- 2025-11-05
- DOI
- https://doi.org/10.1111/bju.70065
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00